SUGAR LAND--June 4, 2008 Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- In addition to developing drugs for the marketplace the old fashioned way, with benefit of labs and scientists, pharma-biotech companies are increasingly turning to cash to pay for mergers and acquisitions that will hopefully fill their pipelines. Companies featured: AstraZeneca (NYSE:AZN), Schering-Plough (NYSE:SGP), Mylan Laboratories (NYSE:MYL), Merck & Company (NYSE:MRK), Emergent BioSolutions Inc. (NYSE:EBS), Bristol-Myers Squibb Company (NYSE:BMY), Kosan Biosciences Inc. (NASDAQ:KOSN)